ISCOM™-based vaccines: The second decade

Immunology and Cell Biology

Volumn 83, Issue 2, 2005, Pages 119-128

  Sanders, Megan T ^a   Brown, Lorena E ^a   Deliyannis, Georgia ^a   Pearse, Martin J ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSL LIMITED   (Australia)

Author keywords

Adjuvant; Immune response; Immunotherapy; ISCOM; ISCOMATRIX

Indexed keywords

ADJUVANT; ISCOM; ISCOMATRIX; VACCINE; ANTIGEN; CHOLESTEROL; PHOSPHOLIPID; SAPONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTATION; CHEMICAL COMPOSITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; EPSTEIN BARR VIRUS; GNOTOBIOTICS; GUINEA PIG; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLUENZA VIRUS; JAPANESE ENCEPHALITIS VIRUS; MACACA; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; OPSONIZATION; PARTICLE SIZE; PHAGOCYTOSIS; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; ROTAVIRUS; TRANSMISSION ELECTRON MICROSCOPY; VIRUS NEUTRALIZATION; ANIMAL; CD8+ T LYMPHOCYTE; DRUG COMBINATION; ELECTRON MICROSCOPY; IMMUNE SYSTEM; IMMUNOLOGY;

ANIMALIA;

ANIMALS; ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CHOLESTEROL; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNE SYSTEM; ISCOMS; MICE; MICROSCOPY, ELECTRON; PHOSPHOLIPIDS; SAPONINS;

EID: 16344393356     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2005.01319.x     Document Type: Review

References (84)

1. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308: 457-60.
2. Sjolander A, Drane D, Maraskovsky E et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine 2001; 19: 2661-5.
3. Smith RE, Donachie AM, Grdic D, Lycke N, Mowat AM. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J. Immunol. 1999; 162: 5536-46.
4. Robson NC, Beacock-Sharp H, Donachie AM, Mowat AM. Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading. Immunology 2003; 109: 374-83.
5. Windon RG, Chaplin PJ, Beezum L et al. Induction of lymphocyte recruitment in the absence of a detectable immune response. Vaccine 2000; 19: 572-8.
6. Claassen IJ, Osterhaus AD, Claassen E. Antigen detection in vivo after immunization with different presentation forms of rabies virus antigen: involvement of marginal metallophilic macrophages in the uptake of immune-stimulating complexes. Eur. J. Immunol. 1995; 25: 1446-52.
7. Kersten G, Drane D, Pearse M, Jiskoot W, Coulter A. Liposomes and ISCOMS. In: Kaufmann S (ed.) Novel Vaccination Strategies. Weinheim: Wiley-VCH, 2004; 173-96.
8. Sambhara S, Woods S, Arpino R et al. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. J. Infect. Dis. 1998; 177: 1266-74.
9. Sjotander S, Drane D, Davis R, Beezum L, Pearse M, Cox J. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses. Vaccine 2001; 19: 4072-80.
10. da Fonseca DP, Frerichs J, Singh M, Snippe H, Verheul AF. Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis. Vaccine 2001; 19: 122-31.
11. Hu KF, Ekstrom J, Merza M, Lovgren-Bengtsson K, Morein B. Induction of antibody responses in the common mucosal immune system by respiratory syncytical virus immunostimulating complexes. Med. Microbiol. Immunol. 1999; 187: 191-8.
12. Hu KF, Elvander M, Merza M, Akerblom L, Brandenburg A, Morein B. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin. Exp. Immunol. 1998; 113: 235-43.
13. Peeters CC, Claassen IJ, Schuller M, Kersten GF, van der Voort EM, Poolman JT. Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice. Vaccine 1999; 17: 2702-712.
14. Tarpey I, Stacey SN, McIndoe A, Davies DH. Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs). Vaccine 1996; 14: 230-36.
15. Yeolekar LR, Banerjee K. Immunogenicity of immunostimulating complexes of Japanese encephalitis virus in experimental animals. Acta Virol. 1996; 40: 245-50.
16. van Pinxteren LA, Bruce MG, Campbell I et al. Effect of oral rotavirus/iscom vaccines on immune responses in gnotobiotic lambs. Vet. Immunol. Immunopathol. 1999; 71: 53-67.
17. Wilson AD, Lovgren-Bengtsson K, Villacres-Ericsson M, Morein B, Morgan AJ. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines. Vaccine 1999; 17: 1282-90.
18. Polakos NK, Drane D, Cox J et al. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J. Immunol. 2001; 166: 3589-98.
19. Verschoor EJ, Mooij P, Oostermeijer H et al. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. J. Virol. 1999; 73: 3292-300.
20. Sjolander A, Cox JC, Barr IG. ISCOMs: an adjuvant with multiple functions. J. Leukoc. Biol. 1998; 64: 713-23.
21. Sjolander A, van't Land B, Lovgren-Bengtsson K. Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol. 1997; 177: 69-76.
22. Klaus GG, Pepys MB, Kitajima K, Askonas BA. Activation of mouse complement by different classes of mouse antibody. Immunology 1979; 38: 687-95.
23. 2 anti-hapten antibodies in mice. Eur. J. Immunol 1985; 15: 793-8.
24. 2a restriction of murine antibodies elicited by viral infections. J. Exp. Med. 1987; 165: 64-9.
25. Kipps TJ, Parham P, Punt J, Herzenberg LA. Importance of immunogtobutin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J. Exp. Med. 1985; 161: 1-17.
26. Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990; 344: 873-5.
27. Guan XJ, Wu YZ, Jia ZC, Shi TD, Tang Y. Construction and characterization of an experimental ISCOMS-based hepatitis B polypeptide vaccine. World J. Gastroenterol. 2002; 8: 294-7.
28. Le TT, Drane D, Malliaros J et al. Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. Vaccine 2001; 19: 4669-75.
29. Maraskovsky E, Sjolander S, Drane DP et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin. Cancer Res. 2004; 10: 2879-90.
30. Morein F, Bengtsson KL. Functional aspects of iscoms. Immunol. Cell Biol. 1998; 76: 295-9.
31. Osterhaus A, van Amerongen G, van Binnendijk R. Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine. Vaccine 1998; 16: 1479-81.
32. Lenarczyk A, Le TT, Drane D et al. ISCOM based vaccines for cancer immunotherapy. Vaccine 2004; 22: 963-74.
33. Dong-Ji Z, Yang X, Shen C, Lu H, Murdin A, Brunham RC. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunolobulin A and Th1 cellular immune responses. Infect. Immun. 2000; 68: 3074-8.
34. Igietseme JU, Murdin A. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes. Infect. Immun. 2000; 68: 6798-806.
35. Mohamedi SA, Brewer JM, Alexander J, Heath AW, Jennings R. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems. Vaccine 2000; 18: 2083-94.
36. Deliyannis G, Jackson DC, Dyer W et al. Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine 1998; 16: 2058-68.
37. Lin WR, Jennings R, Smith TL, Wozniak MA, Itzhaki RF. Vaccination prevents latent HSV1 infection of mouse brain. Neurobiol. Aging 2001; 22: 699-703.
38. Golovliov I, Ericsson M, Akerblom L, Sandstrom G, Tarnvik A, Sjostedt A. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis. Vaccine 1995; 13: 261-7.
39. de Vries P, van Binnendijk RS, van der Marel P et al. Measles virus fusion protein presented in an immune-stimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice. J. Gen. Virol. 1988; 69: 549-59.
40. Varsanyi TM, Morein B, Love A, Norrby E. Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein. J. Virol. 1987; 61: 3896-901.
41. Wyde PR, Stittelaar KJ, Osterhaus AD, Guzman E, Gilbert BE. Use of cotton rats for preclinical evaluation of measles vaccines. Vaccine 2000; 19: 42-53.
42. Simms JR, Heath AW, Jennings R. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs. J. Infect. Dis. 2000; 181: 1240-48.
43. Rimmelzwaan GF, Claas EC, van Amerongen G, de Jong JC. Osterhaus AD. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 1999; 17: 1355-8.
44. Iosef C, Van Nguyen T, Jeong K et al. Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes. Vaccine 2002; 20: 1741-53.
45. Gonzalez AM, Nguyen TV, Azevedo MS et al. Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM. Clin. Exp. Immunol. 2004; 135: 361-72.
46. de Vries P, Heeney JL, Boes J et al. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. Vaccine 1994; 12: 1443-52.
47. Rimmelzwaan GF, Baars M, van Beek R et al. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J. Gen. Virol. 1997; 78: 757-65.
48. van Binnendijk RS, Poelen MC, van Amerongen G, de Vries P, Osterhaus AD. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 1997; 175: 524-32.
49. Putkonen P, Bjorling E, Akerblom L et al. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. J. Acquir. Immune Defic. Syndr. 1994; 7: 551-9.
50. Heeney JL, van Gils ME, van der Meide P et al. The role of type-1 and type-2 T-helper immune responses in HIV-1 vaccine protection. J. Med. Primatol. 1998; 27: 50-58.
51. Heeney JL, Teeuwsen VJ, van Gils M et al. beta-Chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc. Natl Acad. Sci. USA 1998; 95: 10803-808.
52. Heeney J, Akerblom L, Barnett S et al. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunol. Lett. 1999; 66: 189-95.
53. Akerblom L, Nara P, Dunlop N, Putney S, Morein B. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products. Biotechnol. Ther. 1993; 4: 145-61.
54. Heeg K, Kuon W, Wagner H. Vaccination of class I major histocompatibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: immunostimulating-ovalbumin complexes enter the class 1 MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. Eur. J. Immunol. 1991; 21: 1523-7.
55. Pyle SW, Morein B, Bess JW Jr et al. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120). Vaccine 1989; 7: 465-73.
56. Morein B, Ekstrom J, Lovgren K. Increased immunogenicity of a non-amphipathic protein (BSA) after inclusion into iscoms. J. Immunol. Methods 1990; 128: 177-81.
57. Weiss HP, Stitz L, Becht H. Immunogenic properties of ISCOM prepared with influenza virus nucleoprotein. Arch. Virol. 1990; 114: 109-20.
58. Reid G. Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid. Vaccine 1992; 10: 597-602.
59. Pedersen IR, Bog-Hansen TC, Dalsgaard K, Heegaard PM. Iscom immunization with synthetic peptides representing measles virus hemagglutinin. Virus Res. 1992; 24: 145-59.
60. Kazanji M, Laurent F, Pery P. Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of Eimeria falciformis in ISCOMs. Vaccine 1994; 12: 798-804.
61. Browning M, Reid G, Osborne R, Jarrett O. Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies. Vaccine 1992; 10: 585-90.
62. Mowat AM, Donachie AM, Reid G, Jarrett O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 1991; 72: 317-22.
63. Hsu SC, Schadeck EB, Delmas A, Shaw M, Steward MW. Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunization. Vaccine 1996; 14: 1159-66.
64. Agrawal L, Haq W, Hanson CV, Rao DN. Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity. J. Immune Based Ther. Vaccines 2003; 1: 5.
65. Voeten JT, Rimmelzwaan GF, Nieuwkoop NJ, Lovgren-Bengtsson K, Osterhaus AD. Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8 (+) cytotoxic T lymphocytes. Vaccine 2000; 19: 514-22.
66. Andersson C, Sandberg L, Murby M, Sjolander A, Lovgren-Bengtsson K, Stahl S. General expression vectors for production of hydrophobically tagged immunogens for direct iscom incorporation. J. Immunol. Methods 1999; 222: 171-82.
67. Malliaros J, Quinn C, Arnold FH et al. Association of antigens to ISCOMATRIX adjuvant using metal chelation leads to improved CTL responses. Vaccine 2004; 22: 3968-75.
68. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 2000; 165: 4778-82.
69. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002; 20: 2431-8.
70. Morein B, Villacres-Eriksson M, Lovgren-Bengtsson K. Iscom, a delivery system for parenteral and mucosal vaccination. Dev. Biol. Stand. 1998; 92: 33-9.
71. Sjolander A, Cox JC. Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. Adv. Drug Deliv. Rev. 1998; 34: 321-38.
72. Coulter A, Harris R, Davis R et al. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 2003; 21: 946-9.
73. Ugozzoli M, O'Hagan DT, Ott GS. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology 1998; 93: 563-71.
74. Carol H, Nieto A. A mucosal IgA response, but no systemic antibody response, is evoked by intranasal immunisation of dogs with Echinococcus granulosus surface antigens iscoms. Vet. Immunol. Immunopathol. 1998; 65: 29-41.
75. Tamura S, Miyata K, Matsuo K et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol. 1996; 156: 3892-900.
76. Levi R, Aboud-Pirak E, Leclerc C, Lowell GH, Arnon R. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Vaccine 1995; 13: 1353-9.
77. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308: 457-60.
78. Frazer IH, Quinn M, Nicklin JL et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX™ adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004; 23: 172-81.
79. Davis ID, Chen W, Jackson H et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4 (+) and CD8 (+) T cell responses in humans. Proc. Natl Acad. Sci. USA 2004; 101: 10 697-702.
80. Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 1999; 259: 256-61.
81. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2001; 19: 1180-87.
82. Sambhara S, Kurichh A, Miranda R et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol. 2001; 211: 143-53.
83. Jackson DC, Tang XL, Brown LE, Murray JM, White DO, Tregear GW. Antigenic determinants of influenza virus hemagglutinin. XII. The epitopes of a synthetic peptide representing the C-terminus of HA1. Virology 1986; 155: 625-32.
84. Deliyannis G, Jackson DC, Ede NJ et al. Induction of long-term memory CD8 (+) T cells for recall of viral clearing responses against influenza virus. J. Virol. 2002; 76: 4212-21.